Transcatheter vacuum-assisted left-sided mass extraction with the AngioVac system.

Area of Science:

• Cardiovascular Interventions
• Medical Device Technology
• Minimally Invasive Surgery

Background:

• The AngioVac system is FDA-approved for right-sided transcatheter vacuum-assisted mass extraction (TVME).
• Its application for left-sided TVME remains limited, necessitating further investigation.
• TVME offers a less invasive alternative to open surgery for mass removal.

Purpose of the Study:

• To evaluate the safety and efficacy of the AngioVac system for left-sided TVME.
• To assess the feasibility of using AngioVac in a clinical setting for left-sided mass extraction.
• To identify potential complications and success rates associated with left-sided TVME using AngioVac.

Main Methods:

• A retrospective review of consecutive patients undergoing left-sided TVME with the AngioVac system at two Michigan centers.
• Data collection included patient demographics, procedural details, and in-hospital/follow-up events.
• Technical success was defined as 70%-100% material aspiration; bilateral cerebro-embolic protection was employed.

Main Results:

• Ten patients (50% male, mean age 58.3 years) with recurrent embolic events underwent the procedure.
• Successful aspiration was achieved in 80% of cases, with a mean aspiration time of 9.3 minutes.
• No complications were reported during the follow-up period (1-16 months).

Conclusions:

• The AngioVac system appears feasible and safe for left-sided mass extraction in this small case series.
• The findings suggest potential for AngioVac as an alternative to surgery for specific indications.
• Larger trials are warranted to establish definitive effectiveness and safety for potential on-label use.